drugset / Trial / NCT04783545
Phase I Study of VLX-1005 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration. Other exploratory objectives are: To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration.
Timeline
- Start
- 2021-03-24
- Primary completion
- 2022-01-11
- Completion
- 2022-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VLX-1005 | Small molecule | — | Intravenous |
Indications
No indication recorded.